Administrative Core
行政核心
基本信息
- 批准号:10673745
- 负责人:
- 金额:$ 18.46万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-11 至 2027-07-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAdvocateAnimalsBrainBrain NeoplasmsBudgetsCancer CenterCancer PatientClinicalCollaborationsCommittee MembersCommunicationComprehensive Cancer CenterContractsDataDedicationsDevelopmentDiagnosisDoctor of PhilosophyEducational workshopEnsureEvaluationGoalsGrantHumanIndustryInformation DisseminationInstitutionIntranetLeadershipMaintenanceMalignant neoplasm of brainMinorityMinority RecruitmentMonitorOccupational activity of managing financesOrganPatientsPoliciesPrincipal InvestigatorPrognosisProgress ReportsPublicationsRecordsRegulationResearchResearch PersonnelResearch Project GrantsResource SharingResourcesScheduleScienceSiteTranslational ResearchUnderrepresented MinorityUnited States National Institutes of HealthUpdateWomancareerclinical applicationdaily functioningdata managementhuman subjectimprovedinnovationmeetingsmemberpatient advocacy groupprogramssymposiumweb sitewebinar
项目摘要
PROJECT SUMMARY/ABSTRACT – Administrative Core
The purpose of the Administrative Core (Core A) is to support the translational objectives of the UCLA
SPORE in Brain Cancer by serving as its organizational hub. The Core is responsible for the oversight and
daily functions of the SPORE and provides organizational, administrative, and scientific leadership (both
basic and clinical) for all of the aspects of the SPORE, including coordination and communication between all
investigators and committee members. It will provide scientific management, including ongoing oversight and
scientific review of all projects and cores to ensure that the stated scientific goals of the SPORE are met.
The Core has ultimate responsibility for the overall financial management of the budget and appropriate filing
of budgetary information. It will organize regularly scheduled meetings and seminars, and provide
commitment of SPORE investigators to attend the annual NCI Brain SPORE Mid-Winter Retreat and other
relevant NCI-related meetings/workshops and activities. The scheduling and organization of an annual UCLA
Brain Cancer SPORE Symposium, including participation of the External Advisory Board (EAB), will be the
responsibility of the Administrative Core. This Core will oversee the administration of the SPORE
Developmental Research (DRP) and Career Enhancement Programs (CEP), while providing oversight and
assuring compliance with all UCLA, NCI, and Federal regulations and requirements, including maintenance of
appropriate animal and human subject approvals and monitoring of all the established policies for the
inclusion of women and underrepresented minorities. It will be the liaison between the SPORE and the NCI-
designated Jonsson Comprehensive Cancer Center, other UCLA academic and administrative bodies,
NIH/NCI staff, IAB/EAB members, and patient advocacy groups. The Administrative Core will also ensure
that data and resources are shared appropriately in order to promote intra- and inter-SPORE collaboration,
provide integrated and centralized data management support through a new UCLA Brain SPORE Data
Management (Brain-SPOD) platform, and maintain/update the UCLA Brain SPORE intranet and website.
The Administrative Core is led by Linda M. Liau, MD, PhD, MDA, the SPORE principal investigator, who
oversees all UCLA Brain Cancer SPORE activities.
项目摘要/摘要--行政核心
管理核心(核心A)的目的是支持加州大学洛杉矶分校的翻译目标
孢子在脑癌中起着组织中枢的作用。核心负责监督和
孢子的日常功能,并提供组织、行政和科学领导(两者
基本的和临床的)孢子的所有方面,包括所有
调查人员和委员会成员。它将提供科学管理,包括持续监督和
对所有项目和核心进行科学审查,以确保达到规定的孢子科学目标。
核心对预算的全面财务管理和适当的归档负有最终责任
预算信息。它将定期组织会议和研讨会,并提供
孢子研究人员承诺参加NCI脑孢子冬至和其他年度务虚会
与NCI相关的会议/讲习班和活动。一年一度的加州大学洛杉矶分校的计划和组织
脑癌孢子研讨会,包括外部咨询委员会(EAB)的参与,将是
行政核心的责任。这个核心将监督孢子的管理
发展研究(DRP)和职业提升计划(CEP),同时提供监督和
确保遵守所有UCLA、NCI和联邦法规和要求,包括维护
适当的动物和人类受试者批准和监测所有已制定的政策
将妇女和代表性不足的少数群体包括在内。它将是孢子和NCI之间的联络人-
被指定为琼森综合癌症中心,其他加州大学洛杉矶分校的学术和行政机构,
NIH/NCI工作人员、IAB/EAB成员和患者倡导团体。行政核心还将确保
适当地共享数据和资源,以促进孢子内和孢子间的合作,
通过新的加州大学洛杉矶分校脑孢子数据提供集成和集中的数据管理支持
管理(Brain-SPOD)平台,维护/更新加州大学洛杉矶分校脑孢子内联网和网站。
管理核心由Linda M.Liau领导,医学博士,博士,MDA,孢子首席研究员,谁
监督加州大学洛杉矶分校所有的脑癌孢子活动。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Linda M Liau其他文献
Linda M Liau的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Linda M Liau', 18)}}的其他基金
Project 1: Active immunotherapy combined with checkpoint modulation for glioblastoma
项目1:主动免疫疗法联合检查点调节治疗胶质母细胞瘤
- 批准号:
10225550 - 财政年份:2017
- 资助金额:
$ 18.46万 - 项目类别:
Novel mouse models using MADR-GESTALT technology to accelerate glioma research
使用 MADR-GESTALT 技术加速神经胶质瘤研究的新型小鼠模型
- 批准号:
10709379 - 财政年份:2017
- 资助金额:
$ 18.46万 - 项目类别:
Incorporation of Novel MADR-GESTALT Technology into UCLA SPORE in Brain Cancer
将新型 MADR-GESTALT 技术纳入 UCLA SPORE 治疗脑癌
- 批准号:
10271986 - 财政年份:2017
- 资助金额:
$ 18.46万 - 项目类别:
Project 1: Active immunotherapy combined with checkpoint modulation for glioblastoma
项目1:主动免疫疗法联合检查点调节治疗胶质母细胞瘤
- 批准号:
9983047 - 财政年份:2017
- 资助金额:
$ 18.46万 - 项目类别:
Incorporation of Novel MADR-GESTALT Technology into UCLA SPORE in Brain Cancer
将新型 MADR-GESTALT 技术纳入 UCLA SPORE 治疗脑癌
- 批准号:
10709378 - 财政年份:2017
- 资助金额:
$ 18.46万 - 项目类别:
Novel mouse models using MADR-GESTALT technology to accelerate glioma research
使用 MADR-GESTALT 技术加速神经胶质瘤研究的新型小鼠模型
- 批准号:
10271987 - 财政年份:2017
- 资助金额:
$ 18.46万 - 项目类别:
相似海外基金
Optimizing Health and Well-Being of Diverse Mothers with IDD and Their Infants During the Perinatal Period: A Virtual Advocate Tool for Data-Driven Supports
优化患有 IDD 的不同母亲及其婴儿在围产期的健康和福祉:用于数据驱动支持的虚拟倡导工具
- 批准号:
10760051 - 财政年份:2023
- 资助金额:
$ 18.46万 - 项目类别:
POSE: Phase II: Advocate Led Long-term Gameplan for Open OnDemand (ALL GOOD)
POSE:第二阶段:倡导者主导 Open OnDemand 的长期游戏计划(一切顺利)
- 批准号:
2303692 - 财政年份:2023
- 资助金额:
$ 18.46万 - 项目类别:
Standard Grant
Capitalising on our differences: A gathering to better understand and advocate for Early Career Health Researchers in Canada
利用我们的差异:更好地理解和倡导加拿大早期职业健康研究人员的聚会
- 批准号:
468168 - 财政年份:2022
- 资助金额:
$ 18.46万 - 项目类别:
Miscellaneous Programs
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
- 批准号:
10427960 - 财政年份:2022
- 资助金额:
$ 18.46万 - 项目类别:
Evaluating an ACEs-Targeting Advocate Model of a Substance Use Prevention Program
评估药物使用预防计划的针对 ACE 的倡导者模型
- 批准号:
10577074 - 财政年份:2022
- 资助金额:
$ 18.46万 - 项目类别:
The Art of Creation: Using Art-Based Knowledge Translation to Promote and Advocate for a Healthy Start to Life
创造的艺术:利用基于艺术的知识转化来促进和倡导健康的生命开端
- 批准号:
486588 - 财政年份:2022
- 资助金额:
$ 18.46万 - 项目类别:
Studentship Programs
When I am Old, I shall Wear Purple Nail Varnish: Utilising performance art to construct queer spaces that celebrate and advocate for ageing bodies
当我老了,我要涂紫色指甲油:利用行为艺术构建酷儿空间,庆祝和倡导衰老的身体
- 批准号:
2760091 - 财政年份:2022
- 资助金额:
$ 18.46万 - 项目类别:
Studentship
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
- 批准号:
10621188 - 财政年份:2022
- 资助金额:
$ 18.46万 - 项目类别:
Techquity by FAITH!: A cluster randomized controlled trial to assess the efficacy of a community-informed, cardiovascular health promotion mobile hlth intervention with digital health advocate support
Techquity by FAITH!:一项整群随机对照试验,旨在评估社区知情、心血管健康促进移动 hlth 干预措施在数字健康倡导者支持下的效果
- 批准号:
10891016 - 财政年份:2021
- 资助金额:
$ 18.46万 - 项目类别:
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
自身抗体阳性受试者的 CMV 反应主张抗病毒治疗以预防 T1D
- 批准号:
10230365 - 财政年份:2020
- 资助金额:
$ 18.46万 - 项目类别: